Searched for
INDIA OBESITY TREATMENT MARKET
Eli Lilly launches cancer drug Tanstrive in IndiaThe launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced ...- Forget power: The unquenchable AI thirst propelling water stocks up to 45%India's water sector is experiencing a surge, with stocks like Shakti Pumps and VA Tech Wabag jumping up to 45% in a month. This rally is f...
- Bodycraft Clinic and Salon raises Rs 120 crore in fundingBodycraft Clinic and Salon has secured Rs 120 crore funding from Singularity AMC to fuel its expansion across India. The integrated beauty,...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- Rupee rebounds, but risks aboundThe rupee has experienced a brief rebound fueled by optimism surrounding the potential reopening of the Hormuz Strait and a decrease in oil...
- Doctors find new non-surgical treatment for osteoarthritis patients that may relieve knee pain in weeksA groundbreaking minimally invasive procedure, knee embolization, is offering new hope for knee osteoarthritis sufferers. Developed by Colu...
- Alembic Pharma gets tentative nod from USFDA for generic cancer drugAlembic Pharmaceuticals has secured tentative approval from the USFDA for its generic Binimetinib tablets. This marks a significant step fo...
- Pfizer CFO Dave Denton to leave company in AugustPfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure r...
- Jeremy Clarkson cancer: The ‘aggressive’ diagnosis he caught early and the symptoms men shouldn’t ignoreJeremy Clarkson has revealed his diagnosis with an aggressive form of prostate cancer, detected last summer and treated with surgery. Prost...
- India among Asia-Pacific's most AI-ready healthcare markets as demand for coordinated care rises: BainIndia is emerging as one of the most AI-ready healthcare markets in the Asia-Pacific region, with a growing number of consumers using gener...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Novartis India launches Pluvicto for prostate cancer treatmentNovartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision...
- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- India risks becoming "unhealthier before it becomes richer," CEA V Anantha Nageswaran warnsIndia faces a health challenge before achieving wealth. Chief Economic Advisor V Anantha Nageswaran points to rising obesity and sedentary ...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- India's weight-loss market grows upThe landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...
Load More
